JADE BIOSCIENCES INC

JBIONASDAQ

🏆 #1747 by market capEarnings Aug 11 · PreUS Equity

$22.35▲ $0.64 (+2.85%)

Live

1h—

24h▲ 2.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.36B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for JBIO.

Trading Snapshot

Day Range: $22.15 – $22.45
52-Week Range: $6.67 – $28.00
Volume: $3.22B
Avg Volume: $2.23B
Shares Outstanding: 60.9M
Next Earnings: Oct 18, 2026

Fundamentals Snapshot

Annual Revenue: $234M
Last Q Revenue: $53M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.06
Dividend Yield: —

Why Investors Own JBIO

✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$234M▲ +24.1% YoY

Gross Margin (TTM)

73.0%▲ +4.0% YoY

Operating Income (TTM)

$65M▲ +24.1% YoY

Free Cash Flow (TTM)

$57M▲ +24.1% YoY

About JADE BIOSCIENCES INC

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

🦦